Mycronic ABOMXSTO: MYCR

MYCR: Record sales, strong margins, and increased dividend highlight robust performance and outlook

· Issued by Mycronic AB

Record Q4 and full-year results with strong sales, order intake, and EBIT margin. All divisions exceeded margin targets, and significant investments in R&D and sales network are planned for 2025. Dividend increased, with continued focus on both organic growth and M&A.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Mycronic AB on 6ix

In the deck

Earlier from Mycronic

Later from Mycronic

All Mycronic news releases